VALIDATED METHOD FOR THE SIMULTANEOUS DETERMINATION OF EMTRICITABINE, BICTEGRAVIR AND TENOFOVIR ALAFENAMIDE IN PHARMACEUTICAL DOSAGE FORM USING UPLC

The proposed study aimed to develop and validate a method for the simultaneous determination of emtricitabine, bictegravir, and tenofovir alafenamide in pharmaceutical dosage form using ultra-ultra dosage performance liquid chromatography (UPLC). The drugs were separated using HSS C18 (100 x 1.8mm, 1.7m) column with a mobile phase composition consisting of 0.1% orthophosphoric acid (pH 2.2) and acetonitrile in the ratio 70:30%v/v at a flow rate of 0.3ml/min. The column temperature was maintained at 30°C, and a detection wavelength of 260nm was used. The retention times were found to be 0.62mins for emtricitabine, 0.89 min for bictegravir and 1.75 min for tenofovir alafenamide. The developed method was validated in accordance with the international conference on harmonization (ICH) guidelines and found to be accurate, precise, specific, and robust. The method obeyed Beer’s law in the 50 – 300µg/ml concentration range for emtricitabine, 12.5 – 75µg/ml for bictegravir and 6.25 – 37.5µg/ml for tenofovir alafenamide, with a correlation coefficient of 0.999. The developed method can be used for the routine quantitative analysis in quality control for the determination of emtricitabine, bictegravir, and tenofovir alafenamide in the pharmaceutical dosage form.